Effect of an Investigational Vaccine for Preventing Staphylococcus aureus Infections After Cardiothoracic Surgery: A Randomized Trial
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Infections due to Staphylococcus aureus are serious complications of cardiothoracic surgery. A novel vaccine candidate (V710) containing the highly conserved S. aureus iron surface determinant B is immunogenic and generally well tolerated in volunteers. OBJECTIVE: To evaluate the efficacy and safety of preoperative vaccination in preventing serious postoperative S. aureus infection in patients undergoing cardiothoracic surgery. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, randomized, event-driven trial conducted between December 2007 and August 2011 among 8031 patients aged 18 years or older who were scheduled for full median sternotomy within 14 to 60 days of vaccination at 165 sites in 26 countries. INTERVENTION: Participants were randomly assigned to receive a single 0.5-mL intramuscular injection of either V710 vaccine, 60 μg (n = 4015), or placebo (n = 4016). MAIN OUTCOME MEASURES: The primary efficacy end point was prevention of S. aureus bacteremia and/or deep sternal wound infection (including mediastinitis) through postoperative day 90. Secondary end points included all S. aureus surgical site and invasive infections through postoperative day 90. Three interim analyses with futility assessments were planned. RESULTS: The independent data monitoring committee recommended termination of the study after the second interim analysis because of safety concerns and low efficacy. At the end of the study, the V710 vaccine was not significantly more efficacious than placebo in preventing either the primary end points (22/3528 V710 vaccine recipients [2.6 per 100 person-years] vs 27/3517 placebo recipients [3.2 per 100 person-years]; relative risk, 0.81; 95% CI, 0.44-1.48; P = .58) or secondary end points despite eliciting robust antibody responses. Compared with placebo, the V710 vaccine was associated with more adverse experiences during the first 14 days after vaccination (1219/3958 vaccine recipients [30.8%; 95% CI, 29.4%-32.3%] and 866/3967 placebo recipients [21.8%; 95% CI, 20.6%-23.1%], including 797 [20.1%; 95% CI, 18.9%-21.4%] and 378 [9.5%; 95% CI, 8.6%-10.5%] with injection site reactions and 66 [1.7%; 95% CI, 1.3%-2.1%] and 51 [1.3%; 95% CI, 1.0%-1.7%] with serious adverse events, respectively) and a significantly higher rate of multiorgan failure during the entire study (31 vs 17 events; 0.9 [95% CI, 0.6-1.2] vs 0.5 [95% CI, 0.3-0.8] events per 100 person-years; P = .04). Although the overall incidence of vaccine-related serious adverse events (1 in each group) and the all-cause mortality rate (201/3958 vs 177/3967; 5.7 [95% CI, 4.9-6.5] vs 5.0 [95% CI, 4.3-5.7] deaths per 100 person-years; P = .20) were not statistically different between groups, the mortality rate in patients with staphylococcal infections was significantly higher among V710 vaccine than placebo recipients (15/73 vs 4/96; 23.0 [95% CI, 12.9-37.9] vs 4.2 [95% CI, 1.2-10.8] per 100 person-years; difference, 18.8 [95% CI, 8.0-34.1] per 100 person-years). CONCLUSIONS AND RELEVANCE: Among patients undergoing cardiothoracic surgery with median sternotomy, the use of a vaccine against S. aureus compared with placebo did not reduce the rate of serious postoperative S. aureus infections and was associated with increased mortality among patients who developed S. aureus infections. These findings do not support the use of the V710 vaccine for patients undergoing surgical interventions. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00518687.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDC definitions for nosocomial infections, 1988
Garner, J. S., Jarvis, W. R., Emori, T. G., Horan, T. C., & Hughes, J. M. (1988) · American Journal of Infection Control · doi:10.1016/0196-6553(88)90053-3 · Cited by 5,672
CDC definitions for nosocomial infections
Yangco, B. G. (1989) · American Journal of Infection Control · doi:10.1016/s0196-6553(89)80013-6 · Cited by 3,770
Interleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409
Group Sequential Methods with Applications to Clinical Trials
Jennison, C., & Turnbull, B. W. (1999) · Chapman & Hall/CRC eBooks · doi:10.1201/9780367805326 · Cited by 1,336
Comparative analysis of two rates
Miettinen, O., & Nurminen, M. (1985) · Statistics in Medicine · doi:10.1002/sim.4780040211 · Cited by 1,110
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Papp, K. A., Leonardi, C., Menter, A., Ortonne, J.-P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H. Z., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109017 · Cited by 941
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Leonardi, C., Matheson, R., Zachariae, C., Cameron, G., Li, L., Edson-Heredia, E., Braun, D., & Banerjee, S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109997 · Cited by 936
Engemann, J. J., Carmeli, Y., Cosgrove, S. E., Fowler, V. G., Bronstein, M. Z., Trivette, S. L., Briggs, J. P., Sexton, D. J., & Kaye, K. S. (2003) · Clinical Infectious Diseases · doi:10.1086/367653 · Cited by 934
Self-citationImmunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms
Rothman, A. L. (2011) · Nature Reviews Immunology · doi:10.1038/nri3014 · Cited by 770
Use of a Staphylococcus aureus Conjugate Vaccine in Patients Receiving Hemodialysis
Shinefield, H., Black, S., Fattom, A., Horwith, G., Rasgon, S., Ordonez, J., Yeoh, H., Law, D., Robbins, J. B., Schneerson, R., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011297 · Cited by 474
Cited by
Methicillin-resistant Staphylococcus aureus
Lee, A. S., de Lencastre, H., Garau, J., Kluytmans, J., Malhotra-Kumar, S., Peschel, A., & Harbarth, S. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.33 · Cited by 1,556
Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus
Foster, T. J., Geoghegan, J. A., Ganesh, V. K., & Höök, M. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3161 · Cited by 1,533
Access to effective antimicrobials: a worldwide challenge
Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Røttingen, J.-A., Klugman, K., & Davies, S. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00474-2 · Cited by 1,465
Skeletal infections: microbial pathogenesis, immunity and clinical management
Masters, E. A., Ricciardi, B. F., Bentley, K. L. D. M., Moriarty, T. F., Schwarz, E. M., & Muthukrishnan, G. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00686-0 · Cited by 735
Challenges in Infective Endocarditis
Cahill, T. J., Baddour, L. M., Habib, G., Hoen, B., Salaun, E., Pettersson, G. B., Schäfers, H. J., & Prendergast, B. D. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.066 · Cited by 715
Staphylococcal manipulation of host immune responses
Thammavongsa, V., Kim, H. K., Missiakas, D., & Schneewind, O. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3521 · Cited by 598
Masters, E. A., Trombetta, R. P., de Mesy Bentley, K. L., Boyce, B. F., Gill, A. L., Gill, S. R., Nishitani, K., Ishikawa, M., Morita, Y., Ito, H., et al. (2019) · Bone Research · doi:10.1038/s41413-019-0061-z · Cited by 575
“aureus bacteremia.(154) This clinical trial and several others were either terminated abruptly by the FDA or showed no efficacy in humans.”
BackgroundThe role of vaccines in combatting antimicrobial resistance
Micoli, F., Bagnoli, F., Rappuoli, R., & Serruto, D. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00506-3 · Cited by 500
Delany, I., Rappuoli, R., & De Gregorio, E. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201403876 · Cited by 420
Holland, T. L., Baddour, L. M., Bayer, A. S., Hoen, B., Miro, J. M., & Fowler, V. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.59 · Cited by 406
Self-citationInfection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update
Saiman, L., Siegel, J. D., LiPuma, J. J., Brown, R. F., Bryson, E. A., Chambers, M. J., Downer, V. S., Fliege, J., Hazle, L. A., Jain, M., et al. (2014) · Infection Control & Hospital Epidemiology · doi:10.1086/676882 · Cited by 387
Neutrophils Versus Staphylococcus aureus: A Biological Tug of War
Spaan, A. N., Surewaard, B. G. J., Nijland, R., & van Strijp, J. A. G. (2013) · Annual Review of Microbiology · doi:10.1146/annurev-micro-092412-155746 · Cited by 307
Pathogenesis of Staphylococcus aureus Bloodstream Infections
Thomer, L., Schneewind, O., & Missiakas, D. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044351 · Cited by 292
Role of Protein A in the Evasion of Host Adaptive Immune Responses by Staphylococcus aureus
Falugi, F., Kim, H. K., Missiakas, D. M., & Schneewind, O. (2013) · mBio · doi:10.1128/mbio.00575-13 · Cited by 277
Recent developments in understanding the iron acquisition strategies of gram positive pathogens
Sheldon, J. R., & Heinrichs, D. E. (2015) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuv009 · Cited by 272
“In a subsequent trial, however, V710 failed to reduce the incidence of post-operative staphylococcal disease in patients undergoing cardiothoracic surgery, and in fact was associatedwith increasedmortality among subjects who did develop such an infection, although the reasons for this remain unknown (Fowler et al. 201…”
BackgroundPrevention and treatment of Staphylococcus aureus biofilms
Bhattacharya, M., Wozniak, D. J., Stoodley, P., & Hall-Stoodley, L. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1100533 · Cited by 265
Where does a Staphylococcus aureus vaccine stand?
Fowler, V. G., & Proctor, R. A. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12570 · Cited by 241
“Fifth, V710 showed excess numbers of MRSA in vaccinated patients [2].”
BackgroundSelf-citationIron acquisition strategies of bacterial pathogens
Sheldon, J. R., Laakso, H. A., & Heinrichs, D. E. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.vmbf-0010-2015 · Cited by 219
Antibiotic effectiveness: Balancing conservation against innovation
Laxminarayan, R. (2014) · Science · doi:10.1126/science.1254163 · Cited by 170
Spaan, A. N., Vrieling, M., Wallet, P., Badiou, C., Reyes-Robles, T., Ohneck, E. A., Benito, Y., de Haas, C. J. C., Day, C. J., Jennings, M. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6438 · Cited by 166
McNeely, T. B., Shah, N. A., Fridman, A., Joshi, A., Hartzel, J. S., Keshari, R. S., Lupu, F., & DiNubile, M. J. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.34407 · Cited by 99
Self-citationIron acquisition in the cystic fibrosis lung and potential for novel therapeutic strategies
Tyrrell, J., & Callaghan, M. (2016) · Microbiology · doi:10.1099/mic.0.000220 · Cited by 56
Iron Acquisition Strategies of Bacterial Pathogens
Sheldon, J. R., Laakso, H. A., & Heinrichs, D. E. (2016) · Virulence Mechanisms of Bacterial Pathogens · doi:10.1128/9781555819286.ch3 · Cited by 25
Metadata
- Authors
- Fowler, V. G., Allen, K. B., Moreira, E. D., Moustafa, M., Isgro, F., Boucher, H. W., Corey, G. R., Carmeli, Y., Betts, R., Hartzel, J. S., Chan, I. S. F., McNeely, T. B., Kartsonis, N. A., Guris, D., Onorato, M. T., Smugar, S. S., DiNubile, M. J., & Sobanjo-ter Meulen, A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-04-03
- Volume
- 309
- Issue
- 13
- Pages
- 1368
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2086165685
- Cited by
- 372
- References
- 41
- FWCI
- 27.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.